PMID: 9420063Jan 7, 1998Paper

Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment

Antimicrobial Agents and Chemotherapy
H J SchaadM Stewart

Abstract

This open-label study enrolled five subjects with biopsy-proven cirrhosis and moderate to severe hepatic impairment (Child-Pugh classification grade B or C) and five age- and gender-matched controls. All subjects received a single 40-mg oral dose of stavudine (d4T). Stavudine pharmacokinetics in subjects with hepatic impairment were similar to those in age- and gender-matched control subjects and were not substantially different from those previously observed in human immunodeficiency virus-infected patients. Based on these findings, stavudine use does not require modification of the dose or dosing interval for patients with liver disease.

References

Jan 1, 1976·Nephron·D W Cockcroft, M H Gault
Sep 1, 1992·The Journal of Infectious Diseases·M N DudleyK Mayer
Aug 1, 1973·The British Journal of Surgery·R N PughR Williams
Dec 1, 1984·Journal of Pharmacokinetics and Biopharmaceutics·C S Locke
Oct 1, 1980·Journal of Pharmacokinetics and Biopharmaceutics·S Riegelman, P Collier
Mar 1, 1995·The Journal of Infectious Diseases·G Skowron
Mar 1, 1995·The Journal of Infectious Diseases·H W MurrayL M Dunkle

❮ Previous
Next ❯

Citations

Dec 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·David L Wyles, John G Gerber
Jan 8, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Lian ZhouRamaswamy A Iyer
Apr 28, 2006·Antimicrobial Agents and Chemotherapy·Xiao-Jian ZhouNathaniel A Brown
Dec 24, 2015·Expert Review of Clinical Pharmacology·M A PenaP Zapater
Apr 29, 2021·Cancer Chemotherapy and Pharmacology·Nikolay GrechkoJim Xiao
Oct 2, 2004·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Vishal S NarangShrinivas Purandare
Jun 18, 2010·Enfermedades infecciosas y microbiología clínica·UNKNOWN Panel de Expertos de Gesida, UNKNOWN Plan Nacional sobre el Sida
Sep 17, 2011·Journal of Pharmaceutical Sciences·Arthur L L SilvaDirk M Barends

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.